| scholarly article | Q13442814 |
| P2093 | author name string | Ping Zhao | |
| Shiew-Mei Huang | |||
| Fang Wu | |||
| Masoud Jamei | |||
| Lu Gaohua | |||
| Sue-Chih Lee | |||
| Edward D Bashaw | |||
| P2860 | cites work | Inhibition of CYP2C19 and CYP3A4 by omeprazole metabolites and their contribution to drug-drug interactions | Q24611315 |
| Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter? | Q28280141 | ||
| Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions | Q34012134 | ||
| Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole | Q34320782 | ||
| Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies | Q34430052 | ||
| Stereoselective pharmacokinetics and pharmacodynamics of anti-asthma agents | Q34579642 | ||
| Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients. | Q35826204 | ||
| Stereoselective disposition of proton pump inhibitors | Q37136970 | ||
| Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice. | Q37978192 | ||
| The role of physiologically based pharmacokinetic modeling in regulatory review | Q37982653 | ||
| PBPK as a tool in regulatory review | Q37986722 | ||
| Population pharmacokinetic modeling and deconvolution of enantioselective absorption of eflornithine in the rat. | Q39212655 | ||
| Predicting drug interaction potential with a physiologically based pharmacokinetic model: a case study of telithromycin, a time-dependent CYP3A inhibitor | Q39643626 | ||
| Stereoselective sulfation of albuterol in humans. Biosynthesis of the sulfate conjugate by HEP G2 cells. | Q41586189 | ||
| The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel | Q42728694 | ||
| Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. | Q43817651 | ||
| Influence of fluconazole on the pharmacokinetics of omeprazole in healthy volunteers | Q43947373 | ||
| Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy: pharmacokinetic considerations | Q44073432 | ||
| A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects | Q45172356 | ||
| Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. | Q45901623 | ||
| Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection | Q46542648 | ||
| Enantiomer/enantiomer interactions between the S- and R- isomers of omeprazole in human cytochrome P450 enzymes: major role of CYP2C19 and CYP3A4. | Q46644259 | ||
| Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials. | Q51796989 | ||
| Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. | Q52067661 | ||
| Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofen | Q57825141 | ||
| Efficacy and toxicity of ifosfamide stereoisomers in an in vivo rat mammary carcinoma model | Q72092510 | ||
| Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes | Q74020521 | ||
| Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer | Q77732655 | ||
| Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations | Q79488699 | ||
| Effects of CYP2C19 genetic polymorphism on the pharmacokinetics and pharmacodynamics of omeprazole in Chinese people | Q81308858 | ||
| Mechanism of stereoselective interaction between butyrylcholinesterase and ethopropazine enantiomers | Q84527311 | ||
| Stereoselective interaction between tetrahydropalmatine enantiomers and CYP enzymes in human liver microsomes | Q87355297 | ||
| P433 | issue | 8 | |
| P921 | main subject | enantiomer | Q494483 |
| pharmacokinetics | Q323936 | ||
| omeprazole | Q422210 | ||
| P304 | page(s) | 1919-1929 | |
| P577 | publication date | 2014-03-04 | |
| P1433 | published in | Pharmaceutical Research | Q7180737 |
| P1476 | title | Predicting nonlinear pharmacokinetics of omeprazole enantiomers and racemic drug using physiologically based pharmacokinetic modeling and simulation: application to predict drug/genetic interactions | |
| P478 | volume | 31 |
| Q47862592 | Analysis of Nonlinear Pharmacokinetics of a Highly Albumin-Bound Compound: Contribution of Albumin-Mediated Hepatic Uptake Mechanism |
| Q90298395 | Assessing CYP2C19 Ontogeny in Neonates and Infants Using Physiologically Based Pharmacokinetic Models: Impact of Enzyme Maturation Versus Inhibition |
| Q37742001 | Drug-drug interaction of microdose and regular-dose omeprazole with a CYP2C19 inhibitor and inducer. |
| Q41174078 | Evaluating a physiologically based pharmacokinetic model for prediction of omeprazole clearance and assessing ethnic sensitivity in CYP2C19 metabolic pathway |
| Q39926054 | Pharmacokinetic and Pharmacodynamic Modeling Analysis of Intravenous Esomeprazole in Healthy Volunteers |
| Q28088352 | Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification |
| Q50062507 | Predictive Performance of Physiologically Based Pharmacokinetic (PBPK) Modeling of Drugs Extensively Metabolized by Major Cytochrome P450s in Children |
Search more.